Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (08/09/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.

HPV Vaccine Protects Against Genital Warts and Precancerous Growths (07/30/2010)
Results from a recent international study indicate that the vaccine Gardasil® (quadrivalent human papillomavirus [types 6, 11, 16, 18] recombinant vaccine) protects against genital warts and low-grade precancerous changes to the cervix, vulva, and vagina. These findings were published in the journal BMJ.

Many Physicians Fail to Adhere to New Cervical Cancer Screening Guidelines (07/12/2010)
Apparently, old habits die hard: less than one-third of physicians report compliance with the updated guidelines for cervical cancer screening that suggest longer intervals between screening for women with normal test results.

More Than Half of Young Adults in New Relationships Infected with HPV (04/26/2010)
More than half of young adults in a new sexual relationship are infected with human papillomavirus (HPV), and of those 44% were infected with an HPV type that causes cancer, according to the results of a groundbreaking study called the HITCH Cohort Study (HPV Infection and Transmission in Couples through Heterosexual activity).

Cervical Vaccine Provides Little Benefit for Older Women (03/04/2010)
Women over the age of 40 are not likely to benefit from a vaccine designed to prevent human papillomavirus (HPV), according to the results of a study published in the Journal of the National Cancer Institute.1 HPV has been shown to cause cervical cancer.

Cervarix® Protection Extends Beyond Six Years (02/12/2010)
Cervarix®—a vaccine that reduces the risk of cervical cancer by protecting against two high-risk types of human papillomavirus (HPV)—remains effective for more than six years. These results were published in the Lancet.